Biosplice Announces First Patient Dosed in Phase 2 Cirtuvivint Trial
Biosplice Therapeutics has initiated a Phase 2 clinical trial of its CLK/DYRK kinase inhibitor, cirtuvivint, in patients with advanced...
eClinical Tech News
OBI Pharma Announces FDA IND Clearance for Phase 1/2 Study of OBI-902, a TROP-2 Targeting ADC
OBI Pharma, a clinical-stage oncology company, received FDA clearance for an Investigational New Drug (IND) application for OBI-902, a...
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia
Nxera Pharma’s partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist,...
NeuroSigma’s Monarch eTNS System ADHD Trial for Children with Fetal Alcohol Syndrome at UCLA
NeuroSigma, Inc. announced a new clinical trial for its Monarch external Trigeminal Nerve Stimulation (eTNS) device. The trial will...
ABIVAX Completes Enrollment for Phase 3 Ulcerative Colitis Trial
Abivax completed enrollment for its Phase 3 ABTECT trials of obefazimod, a treatment for moderately to severely active ulcerative...
Oncocyte’s Assay Demonstrates Clinical Validity
Oncocyte Corporation announced positive data from a four-year study at Charité University in Berlin, validating its blood-based transplant rejection...
Incyclix Bio’s INX-315 Gets FDA Fast Track for Ovarian Cancer
Incyclix Bio‘s CDK2 inhibitor, INX-315, has received FDA Fast Track designation for treating CCNE1-amplified, platinum-resistant/refractory ovarian cancer. This designation...
Myriad Genetics Presents MRD Data at AACR Meeting
Myriad Genetics presented clinical data at the American Association for Cancer Research (AACR) Annual Meeting showcasing the performance of...
Promising Preclinical Results for Micvotabart Pelidotin
Pyxis Oncology revealed promising preclinical data for its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), at the 2025 American Association...
Starton Therapeutics STAR-LLD Shows Promise in Multiple Myeloma Phase 1b Study
Starton Therapeutics presented positive Phase 1b data for STAR-LLD, a continuous low-dose lenalidomide therapy for relapsed/refractory multiple myeloma (MM),...